CHICAGO, Ill., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Protea Biosciences, a leading developer of products and services for biomolecular analysis, announced today at the 2012 AAPS (American Association of Pharmaceutical Scientists) Annual Meeting, the opening of a dedicated Mass Spectrometry Imaging Center (MSIC). Located in Morgantown, WV, the MSIC offers access to the most advanced biomolecular imaging capabilities, including ultra high resolution mass spectrometry coupled with Protea's revolutionary LAESI® platform.
"Mass Spectrometry coupled with imaging capabilities brings biology to a new level of investigation, providing relevant information on the distribution of specific molecules in a tissue," said Alessandro Baldi PhD, Protea's Vice President and General Manager. "The Center has been designed to support customers who require imaging projects, such as drug/ target interaction studies or analysis of the biodynamics of a living population of cells or colonies. This is entirely new science, that we now make available to the global community of biochemists and biologists."
This year Protea introduced a new imaging device known as LAESI DP-1000, that has been recognized as one of the most innovative products of the year, having received both the Frost & Sullivan New Product Innovation Award for Bioanalytics North America, and R&D Magazine's 2012 "R&D 100 Award."
"The MSIC will provide customers and researchers from around the world access to several imaging technologies including our LAESI DP-1000 system, and soon, a new configuration designed for single cell resolution," continued Dr. Baldi. "We are also ready to host customers looking for demonstration of our LAESI product portfolio as well as training. Our Center is positioned to become a worldwide reference for Mass Spectrometry Biomolecular Imaging, a fast growing segment in the bioanalytical market."
About Protea Biosciences Group, Inc.
Protea is a leader in the field of bioanalytics – the identification and characterization of proteins, metabolites, and other biomolecules, which are the products of all living cells and life forms – technology that is foundational for all pharmaceutical and life science research.
Protea's LAESI (Laser Ablation Electrospray Ionization) product portfolio allows for two and three dimensional distribution profiles of molecules in biological samples for unambiguous drug / target interaction studies, as well as the study of bio-dynamics directly from living cell cultures or colonies.
The Protea Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10808
Forward-Looking Statements
This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.